Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises

American Journal of Hypertension

Volumn 12, Issue 7, 1999, Pages 653-664

  Oparil, Suzanne ^a   Aronson, Solomon ^b   Deeb, G Michael ^c   Epstein, Murray ^d   Levy, Jerrold H ^e   Luther, Robert R ^f   Prielipp, Richard ^g   Taylor, Addison ^h  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Neurex Corporation   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Fenoldopam mesylate; Hypertension; Hypertensive crisis; Perioperative hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; CIMETIDINE; DIGOXIN; DOPAMINE RECEPTOR STIMULATING AGENT; ENALAPRIL; ESMOLOL; FENOLDOPAM MESILATE; GLYCERYL TRINITRATE; HALOTHANE; ISRADIPINE; LABETALOL; MORPHINE; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENTOLAMINE; SUXAMETHONIUM; TRIMETAPHAN; VERAPAMIL; WARFARIN;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; VASODILATATION;

ACUTE DISEASE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOPAMINE AGONISTS; FENOLDOPAM; HUMANS; HYPERTENSION; INFUSIONS, PARENTERAL; PERIOPERATIVE CARE;

EID: 0033001332     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(99)00059-X     Document Type: Review

References (31)

1. Calhoun D., Oparil S. Treatment of hypertensive crises. N Engl J Med. 323:1990;1177-1183.
2. National Center for Health Statistics: Vital and Health Statistics: Detailed Diagnoses and Procedures for Patients Discharged From Short-stay Hospitals: United States, 1983-1990. National Health Survey. Hyattsville, MD: Department of Health and Human Services, 1985-1993.
3. Webster J., Petrie J.C., Jeffers T.A., Lovell H.G. Accelerated hypertension-patterns of mortality and clinical factors affecting outcome in treated patients. Q J Med. 86:1993;485-493.
4. Neely C. Postoperative hypertension. Goldmann D., Brown F., Guarnieri D. Perioperative Medicine. 1994;531-542 McGraw-Hill, New York.
5. Beck T.R., Clancy A., Cregeen R.J. Clinical effects of fenoldopam a potent dopamine DA-1 agonist. Hieble J.P.E. Cardiovascular Function of Peripheral Dopamine Receptors. 1990;331-344 Marcel Dekker, New York.
6. Lee M.R. Dopamine and the kidney ten years on . [editorial] Clin Sci. 84:1993;357-375.
7. Denton M.D., Chertow G.M., Brady H.R. "Renal-dose" dopamine for the treatment of acute renal failure scientific rationale, experimental studies and clinical trials . Kidney Int. 50:1996;4-14.
8. Cottee D.B., Saul W.P. Is renal dose dopamine protective or therapeutic? No. Crit Care Clin. 12:1996;687-695.
9. Chiolero R., Borgeat A., Fisher A. Postoperative arrhythmias and risk factors after open heart surgery. Thorac Cardiovasc Surg. 39:1991;81-84.
10. Devins S.S., Miller A., Herndon B.L., O'Toole L., Reisz G. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med. 20:1992;1644-1649.
11. Patel C., Laboy V., Venus B. Uses of sodium nitroprusside in postcoronary bypass surgery a plea for conservatism . Chest. 89:1986;663-667.
12. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
13. Legault C., Furberg C.D., Wagenknecht L.E., et al. Nimodipine neuroprotection in cardiac valve replacement report of an early terminated trial . Stroke. 27:1996;593-598.
14. Pahor M., Guralnik J.M., Furberg C.D., Carbonin P., Havlik R. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. [see comments] Lancet. 347:1996;1061-1065.
15. Epstein M. Calcium antagonists still appropriate as first line antihypertensive agents . Am J Hypertens. 9:1996;110-121.
16. Levy JH: Anaphylactic Reactions in Anesthesia and Intensive Care. Butterworth-Heinemann: Boston, 1992.
17. Harrison D.G., Bates J.N. The nitrovasodilators. New ideas about old drugs. Circulation. 87:1993;1461-1467.
18. Brogden R., Markham A. Fenoldopam. A review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. ADIS Drug Evaluation. 54:1997;634-650.
19. Taylor A.A., Mangoo-Karim R., Luther R.R., Ballard K.D., Pool J.L. Dose-dependent hemodynamic and renal effects of fenoldopam during prolonged infusions in hypertension patients. (abst) Am J Hypertens. 9:1996;117A.
20. Ellis D., Luther R., Fellman J., Mathur V., McGuire D. Treatment of hypertensive emergencies with fenoldopam, a peripherally acting dopamine (DA1) receptor agonist. (abst) Crit Care Med. 26:1998;A23.
21. Panacek E.A., Bednarczyk E.M., Dunbar L.M., Foulke G.E., Holcslaw T. Randomized, prospective trial of fenoldopam vs sodium-nitroprusside in the treatment of acute severe hypertension. Acad Emerg Med. 2:1995;959-965.
22. Gretler D.D., Elliott W.J., Moscucci M., Childers R.W., Murphy M.B. Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam. Arch Intern Med. 152:1992;2445-2448.
23. Aronson S, Roth S, Glock D, Goldberg L, Moss J, Roizen MF: Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoflurane anesthesia in dogs (abst). American Society of Anesthesiologists Annual Meeting 1988;69:A34.
24. Aronson S., Goldberg L.I., Roth S., Glock D., Moss J., Roizen M.F. Preservation of renal blood flow during hypotension induced with fenoldopam in dogs. Can J Anaesth. 37:1990;380-384.
25. Gombotz H., Plaza J., Mahla E., Berger J., Metzler H. DA1-receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension. Acta Anethesiol Scand. 42:1998;834-840.
26. Hill A.J., Feneck R.O., Walesby R.K. A comparison of fenoldopam and nitroprusside in the control of hypertension following coronary artery surgery. J Cardiothorac Vasc Anesth. 7:1993;279-284.
27. Elliott W.J., Weber R.R., Nelson K.S., et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 81:1990;970-977.
28. Shusterman N.H., Elliott W.J., White W.B. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 95:1993;161-168.
29. Young J.B., Leon C.A., Pratt C.M., Kingry C., Taylor A.A., Roberts R. Intravenous fenoldopam in heart failure comparing the hemodynamic effects of dopamine 1 receptor agonism with nitroprusside . Am Heart J. 115:1988;378-384.
30. Carey R.M., Siragy H.M., Ragsdale N.V., et al. Dopamine-1 and dopamine-2 mechanisms in the control of renal function. Am J Hypertens. 3:(6 part 2):1990;59S-63S.
31. Marwick C: FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards [news] [published erratum appears in JAMA 1996 Jun 5;275(21):1638]. JAMA 1996;275:423-424.